Rhythm Pharmaceuticals buy UBS Group AG
Start price
17.12.25
/
50%
€95.50
Target price
17.12.26
-
Performance (%)
-20.94%
Price
17.04.26
€74.00
Summary
This prediction is currently active. The price of Rhythm Pharmaceuticals has decreased since the start of the prediction. Compared to the start price this results in a performance of -20.94%. This prediction currently runs until 17.12.26. The prediction end date can be changed by UBS_Group_AG at any time. UBS_Group_AG has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Rhythm Pharmaceuticals | 3.497% | 3.497% |
| iShares Core DAX® | 3.593% | 3.931% |
| iShares Nasdaq 100 | 5.810% | 5.518% |
| iShares Nikkei 225® | 4.075% | 8.460% |
| iShares S&P 500 | 4.142% | 4.039% |
Comments by UBS_Group_AG for this prediction
In the thread Rhythm Pharmaceuticals diskutieren
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Ratings data for RYTM provided by MarketBeat